BioNTech SE (BioNTech) is a biotechnology platform company with pipeline programs for the treatment of cancer and prevention of infectious disease. The company most prominent platform is for the development of mRNA vaccines.

Scope

This 31-page PowerPoint based report gives an important expert analysis on how COVID-19 will affect BioNTech. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.

Reasons to Buy

An overview of how BioNTech will be affected by the COVID-19 pandemic.

Key Players

BioNTech SE

Table of Contents

1 Executive Summary

2 Company Overview

Key Stats

SWOT Analysis

Sales Overview

3 Regional Analysis

COVID-19 Spread vs. Location of BioNTech Trials

COVID-19 vs. Non-COVID-19 Trials

4 Reaction to COVID-19

BNT-162b2

Insights Exclusive Intel: BioNTech

Global Analyst Consensus Sales Forecast

Upcoming Events

Disrupted Trials

Resumed Trials

Recent Deal Activity

5 Key Findings

6 Appendix

Methodology

About GlobalData

Contacts

$495

Can be used by individual purchaser only

$1,485

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about our multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Testimonial

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods
Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.

Pharmaceuticals
New
Net Present Value Model: (borneol + edaravone)
$500 | November 2022
Pharmaceuticals
New
Net Present Value Model: (Aspirin + Dipyridamole) ER
$500 | November 2022